Showing results (91-100 of 132) with videos related to
Sort By:
Pageof 14
Journal of Clinical Epidemiology|November 4, 2019
Quality of therapeutic drug monitoring guidelines is suboptimal: an evaluation using the Appraisal of Guidelines for Research and Evaluation II instrumentMin Zeng, Qiusha Yi, Linan Zeng, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 4, 2021
Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-GlucuronosyltransferaseYuandong Zheng, Hua Zhang, Mengling Liu, et al.Expert Opinion on Drug Metabolism & Toxicology|May 11, 2025
Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using 14C-radiolabelled techniquesYicong Bian, Jinjie Yuan, Sheng Ma, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|April 4, 2022
Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humansJinghua Yu, Hua Zhang, Yifan Zhang, et al.Frontiers in Pharmacology|November 14, 2024
Prevalence and influence factor of drug-related problems in inpatients with kidney disease: a prospective single central studyGuoguang Gu, Yanping Li, Yunyun Hu, et al.Clinical Pharmacology and Therapeutics|March 5, 2024
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose IndividualizationLing Xue, Guangda Ma, Nick Holford, et al.Journal of Medicinal Chemistry|May 28, 2011
Design and synthesis of small molecule RhoA inhibitors: a new promising therapy for cardiovascular diseases?Jing Deng, Enguang Feng, Sheng Ma, et al.Drug Design, Development and Therapy|March 16, 2026
Effects of Voriconazole on the Safety, Pharmacokinetics and Pharmacodynamics of Ciprofol (HSK3486), a Novel Intravenous Anaesthetic, in Healthy Participants: A Prospective, Randomized, Crossover Clinical TrialYicong Bian, Tao Hu, Qingqing Deng, et al.Expert Opinion on Investigational Drugs|January 15, 2024
Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance studyYicong Bian, Sheng Ma, Qingqing Yao, et al.Mabs|April 11, 2020
Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibodyYan Wang, Donghui Pan, Chenrong Huang, et al.Pageof 14